The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Alert/Advisory
Alerts provide important advice about health products that may include safety information.
-
Ritalin and Artige immediate-release tablets are now also in shortage, and a shortage of Ritalin LA capsules is anticipated.
-
Acne medication warnings further highlight potential risks of mood-related changes and sexual disorders.
-
We are aware of products being sold in Australia that claim to contain, or influence the levels of, nicotinamide adenine dinucleotide (NAD, NAD+, NADH) or nicotinamide mononucleotide (NMN) in the body.
-
New safety warnings for isotretinoin (Roaccutane)
Updates further highlight potential risks of mood-related changes and sexual disorders. -
More prominent warnings about serious side effects for fluoroquinolone antibiotics
More prominent warnings are being added to the product information (PI) and consumer medicine information (CMI) for all oral and injectable (systemic) fluoroquinolones to strengthen existing warnings about serious side effects -
Nitrosamine and Nitroso-structure impurities acceptable intakes update
We are updating information for nitrosamine impurities and other nitroso-structure impurities in medicines including acceptable intakes (AI)
-
Clarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).
-
In consultation with the TGA, Edgewell has taken a precautionary approach and commenced a recall of all batches of these three products from the Australian market.
-
TGA Laboratories has released a report detailing testing of alkyl nitrite products